Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.26.4 (
RNase H
)
2,751
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The major species of human
insulin receptor
mRNA (5.9, 7.5, 8.5 and 10.2 kb) and those in rat tissues (7.4 and 9.6 kb) are each much larger than the 4.2 kb required to encode the insulin receptor precursor. To evaluate the structural basis for this mRNA size heterogeneity, we performed a
ribonuclease H
mapping technique. A small
insulin receptor
cDNA insert was annealed to human and rat poly(A) RNA, followed by site-specific enzymatic cleavage with
ribonuclease H
. Subsequent Northern blot analysis with cDNA probes specific to the 5' end of the cDNA revealed a single fragment from each of the human and rat
insulin receptor
mRNA species. The size of this fragment indicated that each mRNA contains approximately 0.4 kb of 5' untranslated mRNA. In contrast, a 3' region probe demonstrated multiple mRNA fragments after cleavage. The sizes of these fragments indicated that the human
insulin receptor
mRNA species contain from 1.5 to 5.4 kb, and the rat
insulin receptor
mRNAs either 2.8 or 5.3 kb, of 3' untranslated RNA. Thus, the presence of varied, but extensive, 3' untranslated sequences in
insulin receptor
mRNA transcripts accounts for their size heterogeneity and may affect mRNA stability and/or translation efficiency.
...
PMID:Analysis of mRNA heterogeneity by ribonuclease H mapping: application to the insulin receptor. 253 19